Files in this Data Supplement:

• Figure I and Figure II - (TIF) (585 KB) Figure I. Confirmation of reproducible human CMC development after CD34+ cell therapy. In this case, CD34+ cells from another patient were used. Representative double immunofluorescence staining for cTn-I and HNA in each group at day 28. Human CMCs were dose-dependently observed as double positive cells for cTn-I (green) and HNA (red) (x400). White arrows show nuclei of human CMCs. Figure II. Confirmation of reproducible human SMC development after CD34+ cell therapy. In this case, CD34+ cells from another patient were used. Representative double immunofluorescence staining for SMA and HLA-ABC at day 28 in each group (x400). Human vascular SMCs were dose-dependently observed as double positive cells for SMA (green) and HLA-ABC (red). White arrows show human SMCs.
• Figure III - (182 KB) Confirmation of reproducible human EC development after CD34+ cell therapy. In this case, CD34+ cells from another patient were used. Representative double immunofluorescence staining for vWF and HNA in each group at day 28. Human ECs were dose-dependently observed as double positive cells for vWF (green) and HNA (red) (x400). White arrows show nuclei of human ECs.